- This post hoc analysis suggests that compared with insulin glargine 100 U/mL (Gla-100), insulin glargine 300 U/mL (Gla-300) was associated with a reduced risk for nocturnal hypoglycaemia accompanied by comparable glycaemic improvement for people, aged ≥65 and
Why this matters
- The risk for hypoglycaemia and its consequences is higher in older patients with T2DM; however, the safety and efficacy data of basal insulin therapy are limited in these population.
- Meta-analysis included EDITION 1, 2 and 3 trials participants (≥65 and
- Glycaemic efficacy, hypoglycaemia, body weight changes and insulin dosage and adverse events during 6 months’ treatment were evaluated.
- Funding: None.
- Of 2496 participants, 329 and 333 participants were ≥65 years old who received Gla-300 and Gla-100, respectively.
- The least-squares (LS) difference in HbA1c change from baseline to month 6 was comparable for Gla-300 and Gla-100 in participants:
- ≥65 years old; LS mean difference was 0.00% (0.00%; 95% CI, −0.14 to 0.15% [−1.53 to 1.64 mmol/mol]).
- Lesser participants receiving Gla-300 vs Gla-100 experienced nocturnal confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia:
- ≥65 years old (relative risk [RR], 0.70; 95% CI, 0.57-0.85),
- For both age groups, annualised rates of nocturnal confirmed or severe hypoglycaemia were lower with Gla-300 vs Gla-100.
- Post hoc analysis.